By: Sara Riascos  Feb. 15, 2022

Schizophrenia is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. INVEGA SUSTENNA (paliperidone palmitate) is an extended-release antipsychotic drug given by intramuscular injection. Studies have shown that the use of INVEGA SUSTENNA (paliperidone palmitate) is effective six months longer than other common oral antipsychotics in patients with schizophrenia. Resulting in the delay of relapse such as hospitalization, arrest and incarceration. Other studies have shown that the use of INVEGA SUSTENNA (paliperidone palmitate) is associated with a significantly longer time to relapse and less patients to relapse compared to oral antipsychotics. Dexur’s analysis of Real-World Evidence based on Medicare Claims data showed that the use of INVEGA SUSTENNA (paliperidone palmitate) within 7 days of hospitalization was associated with lower hospital readmission rates for Schizophrenia Patients. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of Drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.